Insulin Degludec’s CV Risks Can Be Studied Post-Approval, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The majority of FDA’s Endocrinologic and Metabolic Drugs Advisory Committee agrees the potential advantages of Novo Nordisk’s long-acting basal insulin justify approval before a cardiovascular risk signal seen in a meta-analysis is fully explored in a dedicated outcomes study.